Literature DB >> 15822193

Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs.

Yoshihisa Shitara1, Hitoshi Sato, Yuichi Sugiyama.   

Abstract

Recent studies have revealed the import role played by transporters in the renal and hepatobiliary excretion of many drugs. These transporters exhibit a broad substrate specificity with a degree of overlap, suggesting the possibility of transporter-mediated drug-drug interactions with other substrates. This review is an overview of the roles of transporters and the possibility of transporter-mediated drug-drug interactions. Among the large number of transporters, we compare the Ki values of inhibitors for organic anion transporting polypeptides (OATPs) and organic anion transporters (OATs) and their therapeutic unbound concentrations. Among them, cephalosporins and probenecid have the potential to produce clinically relevant OAT-mediated drug-drug interactions, whereas cyclosporin A and rifampicin may trigger OATP-mediated ones. These drugs have been reported to cause drug-drug interactions in vivo with OATs or OATP substrates, suggesting the possibility of transporter-mediated drug-drug interactions. To avoid adverse consequences of such transporter-mediated drug-drug interactions, we need to be more aware of the role played by drug transporters as well as those caused by drug metabolizing enzymes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15822193     DOI: 10.1146/annurev.pharmtox.44.101802.121444

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  49 in total

1.  A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.

Authors:  Karthik Venkatakrishnan; Michael D Pickard; Lisa L von Moltke
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

Review 2.  Coexistence of passive and carrier-mediated processes in drug transport.

Authors:  Kiyohiko Sugano; Manfred Kansy; Per Artursson; Alex Avdeef; Stefanie Bendels; Li Di; Gerhard F Ecker; Bernard Faller; Holger Fischer; Grégori Gerebtzoff; Hans Lennernaes; Frank Senner
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

3.  Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).

Authors:  Manthena V Varma; Stefanus J Steyn; Charlotte Allerton; Ayman F El-Kattan
Journal:  Pharm Res       Date:  2015-07-09       Impact factor: 4.200

Review 4.  Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions.

Authors:  John D Clarke; Nathan J Cherrington
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-01-27       Impact factor: 4.481

5.  Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.

Authors:  Makiko Kusama; Kazuya Maeda; Koji Chiba; Akinori Aoyama; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2008-12-12       Impact factor: 4.200

6.  Pannexin 1 constitutes the large conductance cation channel of cardiac myocytes.

Authors:  Marie-Cecile Kienitz; Kirsten Bender; Rolf Dermietzel; Lutz Pott; Georg Zoidl
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

7.  How we have learned about the complexity of physiology, pathobiology and pharmacology of bile acids and biliary secretion.

Authors:  Jose J G Marin
Journal:  World J Gastroenterol       Date:  2008-10-07       Impact factor: 5.742

8.  Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.

Authors:  Milin R Acharya; Judith E Karp; Edward A Sausville; Kyunghwa Hwang; Qin Ryan; Ivana Gojo; Jurgen Venitz; William D Figg; Alex Sparreboom
Journal:  Invest New Drugs       Date:  2006-09       Impact factor: 3.850

9.  The role of permeability in drug ADME/PK, interactions and toxicity--presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans.

Authors:  Urban Fagerholm
Journal:  Pharm Res       Date:  2007-08-21       Impact factor: 4.200

Review 10.  Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.

Authors:  Pertti J Neuvonen; Janne T Backman; Mikko Niemi
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.